skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor

Review

(2497) Views  (1928) Full article downloads

Authors: Kade Birkeland, David Parra, Robert Rosenstein

Published Date September 2010 Volume 2010:1 Pages 197 - 219
DOI: http://dx.doi.org/10.2147/JBM.S9650

Kade Birkeland1,2, David Parra1,2, Robert Rosenstein2

1Departments of Medicine and Pharmacy, Veterans Affairs Medical Center, West Palm Beach, FL, USA; 2Department of Medicine, Veterans Affairs Medical Center, West Palm Beach, FL, USA

Abstract: The use of antiplatelet agents, specifically the thienopyridines, has become a standard of care in the approach to the patient presenting with an acute coronary syndrome. These drugs irreversibly inhibit the platelet by permanently binding to the surface P2Y12 receptor and blocking the downstream fibrinogen cross-linking between platelets, which leads to aggregation and thrombus. However, currently available therapeutic choices are limited by potential interaction with other medications, slow hepatic conversion to active metabolite, genetic resistance, and narrow therapeutic safety margin. In order to overcome these disadvantages, there has been an interest in developing alternatives to thienopyridines. Recent investigations have included ticagrelor, a reversible inhibitor of the P2Y12 platelet receptor, which appears to have overcome several drawbacks of the current thienopyridines. Its unique pharmacokinetic and pharmacodynamic profiles result in an inhibition of platelet aggregation that is rapid, high, consistent, and less susceptible to interpatient variability than currently available P2Y12 inhibitors. In addition, ticagrelor offers a potential mortality advantage not apparent with current agents. Although questions regarding the nature, magnitude, and clinical significance of several observed adverse effects (dyspnea and ventricular pauses) remain unanswered, it appears that ticagrelor may represent a significant advancement over currently available oral antiplatelet agents.

Keywords: thienopyridine, clopidogrel, prasugrel, P2Y12, antiplatelet therapy, thrombosis






Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio